Masimo Corporation · NASDAQ:MASI
Masimo — J.P. Morgan Healthcare Conference 2026
19 slides from Masimo's conference presentation, Jan 12, 2026
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference J a n u a r y 1 4 , 2 0 2 6
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, statements about our expectations, plans, strategies or prospects. We generally use the words “may,” “will,” “expect,” “belie
Slide 3: Global Leader in Patient Monitoring
Global Leader in Patient Monitoring (1) Represents estimated installed base of non -invasive technology boards and instruments, excluding handheld and fingertip puls e oximeters, shipped over a rolling 10 -year period ending September 30, 2025. 350+ engineers worldwide 200 million+ patients in 150+
Slide 4: Long History of Driving Strong Financial Results Within Core Med Tech Business
(1) Numbers shown are all Non -GAAP financials. Note: Growth rates and EPS based on preliminary 2025 financial results. Note: Operating margin reflective of guidance range reaffirmed on December 3, 2025. Long History of Driving Strong Financial Results Within Core Med Tech Business 2017 2025E $738 ~
Slide 5: Positioned to Succeed: Long-Range Plan (Targets Through 2028)
Positioned to Succeed Long -Range Plan (Targets Through 2028) Note: Revenue growth excluding the impact of the 53 rd selling week in 2025. 7% –10% Revenue CAGR $8.00 Adj. EPS by 2028 ~$1B 2026 –2028 Cumulative Operating Cash Flow ~30% Operating Margin by 2028 World -class execution -oriented leaders
Slide 6: Masimo Growth Pillars
NPI Up to 1 ppt Ad vanced Monitoring 2.5 –3.0 ppts Int’l Pulse Ox 1.75 –2.25 ppts US Pulse Ox 2.75 –3.75 ppts 6 Note: Revenue growth excluding the impact of the 53 rd selling week in 2025. Masimo Growth Pillars 7% –10% Masimo CAGR 2026 –2028 Elevate Commercial Excellence Proven Markets | Proven Tech
Slide 7: Significant Market Opportunity Across Large Key Markets
Significant Market Opportunity Across Large Key Markets US Pulse Ox Int'l Pulse Ox Advanced Monitoring Continuous Monitoring ~55% Masimo share ~35% Masimo share ~15% Masimo share $1.5B Market 3% –4% Annual Growth ~$800M Market 6% –8% Annual Growth ~$2.5B Market 5% –9% Annual Growth ~45% opportunity
Slide 8: Building Upon Our Commercial Leadership
Building Upon Our Commercial Leadership Winning portfolio supported by real -world evidence Strengthening market -leading commercial channel and elevating marketing strategy Expansive installed base via OEM partnerships with high recurring revenue Deep customer relationships with 98%+ renewal rates
Slide 9: Product portfolio and launches
SET Pulse Ox #1 • Best -in-class accuracy in motion + low perfusion • Used on 200M+ patients globally (1) • Adopted by all top 10 US hospitals (2) 2026/2027 Next -Gen Launch CO -Oximetry* & Hemodynamics #2 • Continuous CO -Ox/Hemoglobin monitoring • LiDCO cardiac output integrated on Root ® monitor
Slide 10: Strengthening Market-Leading Commercial Channel
10 *”New Go to Market” launch planning model. Strengthening Market -Leading Commercial Channel Unified Sales Structure New Chief Commercial Officer New Chief Marketing & Strategy Officer New President, JPAC Region ENHANCED FIELD & MARKETING CAPABILITY ENHANCED MARKETING CAPABILITY Commercial Engine
Slide 11: Installed Base via OEM Partnerships Creates Durable Revenue
Installed Base via OEM Partnerships Creates Durable Revenue Sept. 2025: Multi -Year Partnership Renewal With Broadened Focus 90+ Strong OEM Partnerships Create High Barriers to Entry Large and Growing Installed Base Creates High Recurring Revenue New Philips Partnership With Equivalent Share Gain Op
Slide 12: Deep Customer Relationships With 98%+ Renewal Rates
Deep Customer Relationships With 98%+ Renewal Rates 12 • 50% reduction in unplanned ICU transfers (4) • Blike study (2025) proves cost reduction (5) The Primary Pulse Oximetry at All 10 Top US Hospitals 98%+ Customer Retention Over Past 10 Years ~90% Win -Rate During Head -to- Head Clinical Evaluati
Slide 13: Meaningful Pipeline Delivering Innovations Our Customers Want
Meaningful Pipeline Delivering Innovations Our Customers Want Next -Gen Root ® H & L Acuity Next -Gen Root ® Vital Signs Next -Gen Patient SafetyNet Radius VSM Algorithm Additions: Sepsis O3 Autoregulation Seizure Detection Consumables Elevate commercial excellence and new product launches Wave 1 20
Slide 14: Multi-Year Launch of New Pulse Ox Sensors Begins in 2026
Multi -Year Launch of New Pulse Ox Sensors Begins in 2026 *OEM integration 1 -2 years post -launch. (1) Khanna AK, et al. Prediction of Opioid -Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Ox imetry: An International Prospective, Observational Trial. Anesth Anal
Slide 15: Key Takeaways
Key Takeaways Long -Range Plan (Targets Through 2028) Note: Revenue growth excluding the impact of the 53 rd selling week in 2025. 7% –10% Revenue CAGR $8.00 Adj. EPS by 2028 ~$1B 2026 –2028 Cumulative Operating Cash Flow ~30% Operating Margin by 2028 Finishing the year with a strong foundation to e
Slide 16: 200M Patients and Counting...
200M Patients and Counting... |
Slide 17: Appendix
Appendix + Masino
Slide 18: GAAP to Non-GAAP Reconciliations – Continuing Operations
GAAP to Non -GAAP Reconciliations – Continuing Operations Notes: (1) Totals may not foot due to rounding. Amounts may vary from amounts previously reported due to rounding conventions. (2) The financial information reflects the continuing operations of Masimo’s healthcare business. The sale of the S
Slide 19: GAAP to Non-GAAP Reconciliations – Continuing Operations
GAAP to Non -GAAP Reconciliations – Continuing Operations Notes: (1) Totals may not foot due to rounding. Amounts may vary from amounts previously reported due to rounding conventions. (2) The financial information reflects the continuing operations of Masimo’s healthcare business. The sale of the S